[Alpha Biz= Paul Lee] Celltrion announced that it will finalize the acquisition of Eli Lilly’s U.S. manufacturing plant within the year and immediately initiate facility expansion. The company also confirmed plans to invest approximately KRW 4 trillion to expand domestic production infrastructure.


At an online press briefing on the 19th, Celltrion Group Chairman Seo Jung-jin outlined the company’s next-stage growth strategy, including:

Expansion and future utilization of the Lilly U.S. plant

Large-scale domestic manufacturing investment

Securing a 41-product biosimilar portfolio by 2038


Strengthening new drug development capabilities, including obesity treatments and licensing-in programs


Celltrion emphasized that securing a U.S.-based manufacturing site in the world’s largest pharmaceutical market will eliminate tariff risks for products supplied to the U.S. and enable the company to respond more effectively to growing global demand.


The company plans to complete the acquisition of Eli Lilly’s biopharmaceutical plant in Branchburg, New Jersey within this year, and immediately pursue capacity expansion to maximize production efficiency. The acquisition fully resolves remaining tariff risks even after recent trade negotiations.


Although the plant’s current maximum output already allows for U.S. supply of Celltrion products, the company expects rapid expansion to be necessary due to additional upcoming pipeline products and the scheduled contract manufacturing (CMO) volume for Eli Lilly. As a result, Celltrion plans a phased expansion of the facility.

 

 

[ⓒ 알파경제. 무단전재-재배포 금지]